BHC
Bausch Health Companies Inc.
BHC lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to hold roughly steady.
BHC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Strong | |
| Weak |
BHC's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
BHC PE Valuation
BHC has no meaningful PE right now: it lost money over the past year.
BHC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect BHC's earnings, revenue and profitability to hold roughly steady.
BHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.30 | — |
| Q3 2026 | -$2.29 | -339% |
| Q2 2026 | -$2.96 | -1284% |
| Q1 2026 | -$3.24 | -$3.12 |
| Q4 2025 | $0.42 | +$0.55 |
| Q3 2025 | $0.96 | +$1.44 |
| Q2 2025 | $0.25 | +$1.53 |
| Q1 2025 | -$0.12 | +$1.12 |
| Q4 2024 | -$0.13 | +$1.49 |
BHC has swung to a loss: it lost $2.29 per share over the past year, after a profit the year before.
BHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.9B | +9.7% |
| Q2 2026 | $2.9B | +13% |
| Q1 2026 | $2.5B | +12% |
| Q4 2025 | $2.8B | +9.3% |
| Q3 2025 | $2.7B | +6.8% |
| Q2 2025 | $2.5B | +5.3% |
| Q1 2025 | $2.3B | +4.9% |
| Q4 2024 | $2.6B | +6.3% |
BHC's revenue has grown year over year for 15 quarters in a row: $2.9B last quarter, up 9.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 33% | +10 points |
| Q2 2026 | 26% | +8.4 points |
| Q1 2026 | -38% | -50 points |
| Q4 2025 | 17% | -4.9 points |
| Q3 2025 | 23% | +10 points |
| Q2 2025 | 18% | +1.4 points |
| Q1 2025 | 12% | -0.8 points |
| Q4 2024 | 22% | +6.8 points |
BHC's operating margin was 33% last quarter, up 10 points from the same quarter a year ago, near the top of its range since 2019.
BHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $748M | +138% |
| Q2 2026 | $593M | +212% |
| Q1 2026 | $121M | +26% |
| Q4 2025 | $403M | -19% |
| Q3 2025 | $314M | -6% |
| Q2 2025 | $190M | -37% |
| Q1 2025 | $96M | -26% |
| Q4 2024 | $495M | +70% |
BHC generated $1.9B in free cash flow over the past year, up 70% from the year before.
BHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.6x | High |
| Q2 2026 | 9.2x | High |
| Q1 2026 | 10.9x | High |
| Q4 2025 | 6.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 7.1x | High |
| Q1 2025 | 7.3x | High |
| Q4 2024 | 7.3x | High |
BHC's net debt is about 7.6 years of its operating earnings (EBITDA), up from 6.3 years a year ago.
BHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.2 | Overbought |
| Stochastic | 78.2 | Neutral |
BHC's weekly RSI is 71 (overbought) and its Stochastic is 78 (neutral).
BHC PE vs Healthcare Sector
| Metric | BHC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BHC has no meaningful PE right now: it lost money over the past year.
BHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.86 | 20% above |
| 20 week MA | $6.22 | 33% above |
| 50 week MA | $6.00 | 38% above |
| 100 week MA | $6.22 | 33% above |
| 200 week MA | $7.03 | 17% above |
BHC has climbed back above all five of its weekly moving averages, and it's now 17% above its 200-week average.
BHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.7 | $20.3 | -32% |
| 2021 | $20.3 | $28.0 | +38% |
| 2022 | $28.0 | $6.33 | -77% |
| 2023 | $6.33 | $8.02 | +27% |
| 2024 | $8.02 | $7.65 | -4.6% |
| 2025 | $7.65 | $7.20 | -5.9% |
| 2026 YTD | $7.20 | $8.25 | +15% |
BHC has finished lower in four of the last six years. It's up 15% so far in 2026.